3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
Cyclophosphamide
20
Etoposide
19
Temozolomide
16
Carboplatin
16
Filgrastim
15
Vincristine
11
Cisplatin
11
Radiotherapy
10
Thiotepa
9
Melphalan
8
Granulocyte Colony-Stimulating Factor
8
etoposide phosphate
7
Lomustine
7
Peripheral Blood Stem Cell Transplantation
6
Radiation
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Topotecan
4
Mesna
4
Gemcitabine
4
Busulfan
4
sargramostim
3
gallium Ga 68 dotatate
3
Thalidomide
3
Stem Cell Transplantation
3
Irinotecan
3
Ifosfamide
3
Donepezil
3
Celecoxib
3
Automobiles
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Medulloblastoma
×
olaparib
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled